Page last updated: 2024-10-30

lorazepam and Down Syndrome

lorazepam has been researched along with Down Syndrome in 2 studies

Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)

Research Excerpts

ExcerptRelevanceReference
"Treatment with lorazepam led to improvement in symptoms in all, eventually reversing the catatonia in some children to previous baseline function."1.56Catatonia as a feature of down syndrome: An under-recognised entity? ( Allen, NM; Cahalane, D; Flanagan, O; Lyons, A, 2020)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Lyons, A1
Allen, NM1
Flanagan, O1
Cahalane, D1
Cohen, WI1
Liu, YH1
Stein, MT1

Other Studies

2 other studies available for lorazepam and Down Syndrome

ArticleYear
Catatonia as a feature of down syndrome: An under-recognised entity?
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2020, Volume: 25

    Topics: Adolescent; Anticonvulsants; Catatonia; Child; Down Syndrome; Female; Humans; Lorazepam; Male; Retro

2020
A 7-year-old child with Down syndrome and disruptive behaviors.
    Journal of developmental and behavioral pediatrics : JDBP, 2007, Volume: 28, Issue:2

    Topics: Anti-Anxiety Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorbidity; Diagno

2007